Endocrine therapy is indicated for estrogen receptor (ER)‐positive breast cancer (BC) patients to attenuate the cell supportive effect of estrogens and prevent growth of residual micro‐metastatic disease after surgery. This evidence concerns the gene ESR1 and breast cancer.